Shares of Teladoc Inc (NYSE:TDOC) have been assigned a consensus rating of “Buy” from the nineteen brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $41.62.
Several research analysts recently weighed in on TDOC shares. Canaccord Genuity upped their price target on Teladoc from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Jefferies Group started coverage on Teladoc in a research report on Friday, January 26th. They set a “buy” rating and a $40.00 price target on the stock. KeyCorp reissued a “buy” rating and set a $41.00 price target on shares of Teladoc in a research report on Wednesday, January 10th. Citigroup initiated coverage on Teladoc in a research report on Thursday, January 4th. They issued a “buy” rating on the stock. Finally, Deutsche Bank upped their target price on Teladoc to $45.00 and gave the stock a “buy” rating in a research report on Friday, March 2nd.
NYSE:TDOC traded up $1.15 during trading hours on Friday, hitting $40.30. 769,546 shares of the company’s stock traded hands, compared to its average volume of 1,034,588. The firm has a market capitalization of $2,487.56, a price-to-earnings ratio of -24.42 and a beta of 0.36. Teladoc has a twelve month low of $22.73 and a twelve month high of $44.65. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.37.
In other news, CEO Jason N. Gorevic sold 40,000 shares of the company’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $43.27, for a total transaction of $1,730,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Adam C. Vandervoort sold 27,809 shares of the company’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $38.62, for a total value of $1,073,983.58. Following the sale, the insider now owns 19,338 shares of the company’s stock, valued at approximately $746,833.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 364,494 shares of company stock worth $14,665,947. Insiders own 4.47% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in TDOC. SG Americas Securities LLC bought a new stake in shares of Teladoc during the 4th quarter worth about $101,000. Montag A & Associates Inc. bought a new stake in shares of Teladoc during the 4th quarter worth about $200,000. Xact Kapitalforvaltning AB bought a new stake in shares of Teladoc during the 4th quarter worth about $203,000. Buckley Wealth Management LLC bought a new stake in shares of Teladoc during the 4th quarter worth about $221,000. Finally, California Public Employees Retirement System bought a new stake in shares of Teladoc during the 2nd quarter worth about $260,000.
COPYRIGHT VIOLATION NOTICE: This report was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.wkrb13.com/2018/04/02/brokerages-set-teladoc-inc-tdoc-price-target-at-41-62.html.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.